Table 1. Baseline characteristics of the cohorta.
| Variable | Total | CrAg (+) | CrAg (-) | P-value |
|---|---|---|---|---|
| N | 123 | 10 | 113b | |
| Gender | 0.403 | |||
| Male | 79 (64.2%) | 5 (50%) | 74 (65.5%) | |
| Female | 38 (30.9%) | 5 (50%) | 33 (29.2%) | |
| Transwomen | 6 (4.9%) | 6 (5.3%) | ||
| Age, mean years (SD) | 38 (9.7) | 38 (12.9) | 38 (9.4) | 0.958 |
| Time of HIV Diagnosis at Enrolment | 0.029 | |||
| < 1 year | 34 (27.8%) | 34 (30.4%) | ||
| 1–5 years | 20 (16.4%) | 2 (20%) | 18 (16%) | |
| 5–10 years | 27 (22.1%) | 1 (10%) | 26 (23.2%) | |
| >10 years | 41 (33.6%) | 7 (70%) | 34 (30.4%) | |
| Laboratory Finding | ||||
| CD4 cell count, median cells/mL (IQR) | 46 (18–85) | 38 (14–105) | 46 (19–84) | 0.672 |
| Viral load, median copies/mL (IQR) | 65,609 (21,943–156,299) | 126,468 (32,220–268,637) | 65,609 (21,943–146,883) | 0.371 |
| WHO stage III/IV | 98 (79.6%) | 9 (90%) | 91 (80.5%) | 0.462 |
| Previous opportunistic infection | 60 (48.7%) | 8 (80%) | 52 (46%) | 0.039 |
| Without HAART | 95 (77.2%) | 9 (90%) | 86 (76.1%) | 0.315 |
Abbreviations: HAART, highly active antiretroviral therapy; CrAg, cryptococcal antigenemia; IQR, interquartile; SD, standard deviation; WHO, World Health Organization.
a Data are presented as n (%) or median (IQR) or mean (SD).
b Data was missing for time of HIV diagnosis at enrolment (n = 1).